TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03994913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-CD19 T Cells
Description: The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion.
Study: NCT02831582

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: Given PO.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO.
Study: NCT01654770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: video capsule endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double balloon enteroscopy
Study: NCT01826942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis UltraPulse single fractional CO2 laser treatment thin skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single fractional CO2 treatment at surgical area closure procedure on thick skin
Study: NCT00260988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fragmin (dalteparin)
Description: 200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innohep (tinzaparin)
Description: 175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
Study: NCT01560247

Intervention type: PROCEDURE
Intervention: Mechanical thrombectomy
Description: Mechanical thrombectomy using a MindFrame device
Study: NCT03603522

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioGaia-DSM17938
Description: 2mL per day (1x10\^9 CFU) per day taken orally for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BioGaia-DSM17938
Description: 2mL per day (1x10\^9 CFU) per day taken orally for 28 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator: Placebo Control
Description: 2mL per day of placebo formulation taken orally for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo Control
Description: 2mL per day of placebo formulation taken orally for 28 days
Study: NCT01643330

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a (MYDICAR)
Description: Single intracoronary infusion 1 x 10\^13 DNase Resistant Particles (DRP) MYDICAR

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intracoronary infusion
Study: NCT02728323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 100 mg of Levobupivacaine by intramuscular injection, at the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 20 ml of saline saline by intramuscular injection, at the end of surgery
Study: NCT02524639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
Study: NCT04415346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HU-014 Inj
Description: Clostridium botulinum type A
Study: NCT00781053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P144 cream
Description: P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
Study: NCT00866905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: 40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
Study: NCT03310216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Order I of visual inspection
Description: Participants in group I are provided AI visual inspection system first and EDTRS later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Order II of visual inspection
Description: The participants in Group II are provided EDTRS first and AI visual inspection system later.
Study: NCT02837926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®
Study: NCT02100046

Intervention type: DRUG
Group type: OTHER
Intervention: Zarontin® (ethosuximide) and Stodal®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zarontin® (ethosuximide) and Stodal®
Study: NCT00913341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam Tablets, 1 mg (The Upjohn Company)
Study: NCT01028781

Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
Study: NCT01614470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet, oral use, administered twice a day (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet, oral use, administered twice a day (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet, oral use, administered twice a day (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral use, administered twice a day (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral use, administered twice a day (q12h)
Study: NCT03874442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CliniPup serious game
Description: The interactive game is played at home by the children on a computer or tablet before the surgery. The SERES Pain in Children-game is created with realistic scenarios based on scientific literature about perioperative pain and fear in children. The primary goal of the game is to provide the children insight in the impact of their personal choices on their well-being and on their environment by giving the children information about the day of the surgery. The ultimate aim of the game is to create a change in behaviour, enhance children's coping strategies and reduce the burden of pain and fear in the children and parents.
Study: NCT03456466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2303
Description: 375mg/m2 ，iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 ，iv
Study: NCT02890316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathy remedy
Description: Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation as adjuvant therapy for breast cancer
Description: Daily radiation therapy.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation as adjuvant therapy for breast cancer
Description: Daily radiation therapy.
Study: NCT04195711

Intervention type: DIAGNOSTIC_TEST
Intervention: objective pediatric vision screen, blinq,
Description: hand-held birefringent screener for simultaneous foveation
Study: NCT03447548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback processing speed training
Description: Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Commercially available games on tablet
Study: NCT01832337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb remote ischemic preconditioning (LRIP)
Description: Limb remote ischemic preconditioning (LRIP) consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
Study: NCT04044105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pamphlet education
Description: Patients receive an educational intervention explaining proper opioid disposal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pamphlet education + texts
Description: Patients receive an educational intervention and text message explaining proper opioid disposal
Study: NCT04381078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACE - AudioVisual Guide
Description: Audiovisual guide to Alveolar Bone Graft Procedure, Pre-surgical orthodontics and post-operative care
Study: NCT02992119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01B Fractional dose
Description: RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double RTS,S/AS01E Fractional dose
Description: A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E Standard dose
Description: RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E + DHA-PIP+PQ Standard dose
Description: RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E Fractional dose
Description: RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E + DHA-PIP+PQ Fractional dose
Description: RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose
Description: RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2
Study: NCT02576392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention consisted of a mailing 2 weeks prior to surgery, another 2 weeks post surgery, and a pharmacist intervention if a refill of opioid medication was requested within 90 days of surgery.
Study: NCT02361775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paravertebral catheter
Description: A catheter is placed ultrasound guided at the T5 paravertebral level

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: opioid iv pca
Description: opioid pca consisting of hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.2% ropivacaine infused through paravertebral catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastomeric Pump
Description: Elastomeric pump connected to paravertebral catheter
Study: NCT03435588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS
Description: Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA with ROSE
Description: Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FNB alone
Description: Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
Study: NCT02456194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium Sulfate + Antibiotics + Internal Fixation
Description: STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
Study: NCT03563573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Gluconate Oral Capsule
Description: Each subject will receive a dose of \~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Gluconate Oral Capsule
Description: Each subject will receive a dose of \~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Each subject will receive a dose of \~8 mg/kg of a placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Each subject will receive a dose of \~8 mg/kg of a placebo capsule
Study: NCT04030741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meronem and flagyl
Description: meronem and flagy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Appendectomy as treatment for acute appendicitis
Study: NCT02569892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pascal Retinal Laser Photocoagulator
Description: Sub-threshold macular laser treatment with Pascal laser Endpoint Management System

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pascal Retinal Laser Photocoagulator
Description: Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
Study: NCT04460326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog
Description: Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Fiasp
Description: Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard carbohydrate diet
Description: Standard carbohydrate diet as per usual hospital care (75g with each meal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard carbohydrate diet
Description: Standard carbohydrate diet as per usual hospital care (75g with each meal)
Study: NCT04554589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate 0.2 MG
Description: injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline
Study: NCT02295072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A 5-months physical exercise-based program
Description: The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly.
Study: NCT01499810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral radiofrequency sympathetic renal denervation
Description: Bilateral radiofrequency sympathetic renal denervation is performed as percutaneous transluminal radiofrequency (RF) ablation of neural pathways in the renal artery walls and surrounding tissue using standard equipment for RF ablation of cardiac electrical pathways
Study: NCT04020211

Intervention type: DEVICE
Intervention: Senza HF10 Therapy
Description: Senza 10kHz Spinal Cord Stimulation
Study: NCT02171546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine tablets
Study: NCT02084511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706 solution
Description: Placebo to BI 1026706 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706 solution
Description: Placebo to BI 1026706 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706 solution
Description: Placebo to BI 1026706 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: BI 1026706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: BI 1026706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706 tablet
Description: Placebo to BI 1026706 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706 tablet
Description: Placebo to BI 1026706 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706 tablet
Description: Placebo to BI 1026706 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib capsule
Study: NCT01555658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractioned Heparin
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
Study: NCT03363971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhi Kang Capsule
Description: 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulant agent for Zhi Kang Capsule
Description: 0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
Study: NCT03723434

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-pulse transcranial magnetic stimulation (spTMS)
Description: Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-pulse transcranial magnetic stimulation (spTMS)
Description: Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired associative stimulation (PAS)
Description: Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Description: Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Repetitive TMS (rTMS) will be applied at 1 and 20 Hz with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 300 rTMS pulses will be delivered during 1 and 20 Hz stimulation. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).